- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Halozyme Therapeutics Inc
+ Add to WatchlistHALO:US
7.1700 USD 0.4200 5.53%
Share
As of 17:20:00 ET on 05/22/2013.
More on HALO
News for Halozyme Therapeutics Inc (HALO)
-
COMPANY NEWS
-
PRESS RELEASES
-
INDUSTRY NEWS
- U.S. Stock Options With Biggest Changes in Implied Volatility
- Halogen Software Set to Break 18-Month Canadian Tech IPO Drought
- U.S. Stock Options With Biggest Changes in Implied Volatility
- Halozyme Jumps Most in Six Years on Pfizer Partnership
- U.S. Stocks Rise on China Amid American Budget Talks
- Halozyme Gains on $4 Million Payment: Los Angeles Mover
- U.S. Stock Options With Biggest Changes in Implied Volatility
- U.S. Stock Options With Biggest Changes in Implied Volatility
- U.S. Stock Options With Biggest Changes in Implied Volatility
- U.S. Stocks Fall for 4th Day as ECB’s Draghi Disappoints
- Halozyme Plummets After U.S. Regulators Reject Drug
- U.S. Stock Options With Biggest Changes in Implied Volatility
- Halozyme Falls After FDA Demands More Data: Los Angeles Mover
- Cobalt, Google, Mattel, Spreadtrum: U.S. Equity Movers
- Best Buy, Halozyme, Rick’s, X-Rite: U.S. Equity Movers
- Baxter Receives Marketing Authorization for HyQvia in European Union Published May 21, 2013
- Ignyta Announces Acquisition of Actagene Oncology and Entry into Oncology Personalized Medicine Published May 20, 2013
- Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting Published May 15, 2013
- Halozyme Reports First Quarter 2013 Financial Results Published May 08, 2013
- Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference Published May 07, 2013
- Ignyta and UC San Diego Researchers Find that Permanent Epigenetic Alterations Are Associated with Immune Function in Rheumatoid Published May 06, 2013
- Halozyme to Host First Quarter 2013 Financial Results Conference Call Published May 01, 2013
- Halozyme Initiates Randomized Phase 2 Trial of PEGPH20 in Pancreatic Cancer Published Apr 23, 2013
- Novartis Ramps Up Alzheimer’s Drug Pursuit as Rivals Fail
- Hedge Funds Trail S&P 500 by 10 Percentage Points, Goldman Says
- Addex Rises on Positive Rodent Experiment Results: Zurich Mover
- Novartis Sees MorphoSys Muscle-Atrophy Drug as Exciting
- Teva Bets on Reformulating Old Drugs as Investors Say ‘Show Me’
- Royalty Pharma Raises Elan Bid to $12.50 a Share in Cash
- U.K. to Pilot Illumina Genetic Test for Breast, Ovarian Cancer
- Largest Weekly Option Sentiment Changes for S&P 500 Companies
- SAC Digs In as Deadline Nears for U.S. Insider Cases
- Japan Biotech Firms Jump as Abenomics Cash Spurs Speculation
- Puma Biotech Gains After Rival Drug Data Show No Threat
- Merck KGaA Doesn’t Rule Out Pursuing Lung-Cancer Vaccine
- Billionaire Frost Props Up Prolor Bid With Stock Buys
- U.S. Stock Options With Biggest Changes in Implied Volatility
- Gene-Testing Dispute Focuses on How Much a Patient Should Know
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Advertisements
Advertisement
Rate this Page